PDL-1/PD1 inhibitors: antibody or antinobody? - Wikidata - awgldk - TriplyDB

PDL-1/PD1 inhibitors: antibody or antinobody?

PDL-1/PD1 inhibitors: antibody or antinobody?

http://www.wikidata.org/entity/Q38638443

about

PDL-1/PD1 inhibitors: antibody or antinobody?

http://www.wikidata.org/entity/Q38638443

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

PDL-1/PD1 inhibitors: antibody or antinobody?

@en

type

label

PDL-1/PD1 inhibitors: antibody or antinobody?

@en

prefLabel

PDL-1/PD1 inhibitors: antibody or antinobody?

@en

P1433

Q38638443-92942996-AACE-434D-94EA-4884CC00F8F7

P1476

Q38638443-0EC14342-72B6-442A-B87E-1A9C84B91218

P2093

Q38638443-712DC3CA-9A89-4B61-B7CC-1235BEB868DA

Q38638443-DD782C82-ECAB-483E-AD02-D2352CF0EC0C

Q38638443-EA2F8232-C389-46E4-8434-4AE3CF2E4905

Q38638443-F76DC418-540A-4C22-901E-E77EA6DDE14B

P2860

Q38638443-203D7E60-E86E-4863-9981-776C96FA2A70

Q38638443-2D6D033B-42AF-46FE-A8B0-12A6CF72EDAC

Q38638443-3941BA1B-0285-4489-86D5-D58FA6A014FC

Q38638443-43D46C3C-BC6B-4B41-8D28-8E27B21B0649

Q38638443-6672095B-08F7-43BF-A9A6-41CA45255B04

Q38638443-669A1ACB-D78C-4248-9282-398283692467

Q38638443-7BEEF9E0-86DE-4E78-88E2-42B0B2FBCF7F

Q38638443-8DBA2DBF-8F71-4F36-86D6-9B5774DD5997

Q38638443-93F9EBB6-6133-4838-8C17-3379D997B327

Q38638443-E7267256-C60D-4C71-9451-A98109FB915C

P304

Q38638443-4E23CF6D-E81F-45C0-9A83-A57399FB274B

P31

Q38638443-BC9E6B26-5821-403F-B38C-64369059AF63

Q38638443-f0d2da93-0324-4a31-b458-543c2168cac0

P356

Q38638443-53EF63DB-76DE-4434-94FF-02B513746D4E

P407

Q38638443-2F03DDE7-5F2A-4211-9925-209B2CFE7501

P433

Q38638443-DA4F407E-C2F4-494A-B77B-67613039B2DC

P478

Q38638443-64EBFCD5-6F62-485D-A46F-6494E48295B2

P577

Q38638443-878FC8E0-4125-42F6-918D-F7C51F8663BB

P698

Q38638443-2F531569-0E97-4633-AAF0-18683DF1DE8B

P356

P1433

Future Oncology

P1476

PDL-1/PD1 inhibitors: antibody or antinobody?

@en

P2093

Elie El Rassy

http://www.w3.org/2001/XMLSchema#string

Fouad Aoun

http://www.w3.org/2001/XMLSchema#string

Joseph Kattan

http://www.w3.org/2001/XMLSchema#string

Tarek Assi

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Early-warning signals for critical transitions.

PD-1/PD-L1 inhibitors.

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

Side-effects of checkpoint inhibitor-based combination therapy.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

P304

1669-1671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0215

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28831825

http://www.w3.org/2001/XMLSchema#string